Related content

Compliance with drug therapy for postmenopausal osteoporosis

By Weycker D.   Macarios D.   Edelsberg J.   Oster G.  

Osteoporosis International, Vol. 17, Iss. 11, 2006-11 ,pp. : 1645-1652

Springer Publishing Company

Access to resources Recommend Favorite

The impact of compliance with osteoporosis therapy on fracture rates in actual practice

By Caro J.   Ishak Khajak   Huybrechts Krista   Raggio Gabriel   Naujoks Christel  

Osteoporosis International, Vol. 15, Iss. 12, 2004-12 ,pp. : 1003-1008

Springer Publishing Company

Access to resources Recommend Favorite

Biomarkers for Osteoporosis Management: Utility in Diagnosis, Fracture Risk Prediction and Therapy Monitoring

By Garnero Patrick  

Molecular Diagnosis & Therapy, Vol. 12, Iss. 3, 2008-01 ,pp. : 157-170

Adis International

Access to resources Recommend Favorite

Hormone therapy and risk of non-vertebral fracture: Geelong Osteoporosis Study

By Pasco Julie   Kotowicz Mark   Henry Margaret   Sanders Kerrie   Seeman Ego   Nicholson Geoffrey  

Osteoporosis International, Vol. 15, Iss. 6, 2004-06 ,pp. : 434-438

Springer Publishing Company

Access to resources Recommend Favorite

Prostate Cancer, Osteoporosis and Fracture Risk

By  

Gerontology, Vol. 52, Iss. 2, 2006-02 ,pp. : 107-110

Karger

Access to resources Recommend Favorite